GlassScriptPhysician profile
Olufonso A Ojo
NPI 1316991748
$2,288.25
in general payments reported to CMS, 2019-2025
21 companies · $128 in 2025
The $128 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $298 · 2020: $570 · 2021: $555 · 2022: $249 · 2023: $279 · 2024: $209 · 2025: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $615.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $506.79 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $402.74 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $250.32 | 2019-2023 | Steglatro, Belsomra, Lagevrio |
| Lilly USA, LLC | $224.24 | 2019-2025 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $158.40 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $147.67 | 2021-2024 | |
| Horizon Therapeutics Plc | $85.18 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $77.78 | 2023 | |
| Janssen Pharmaceuticals, INC | $73.22 | 2020 | |
| Abbvie INC. | $61.83 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.58 | 2020-2021 | |
| Allergan, INC. | $45.21 | 2019-2020 | |
| Exact Sciences Corporation | $41.92 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $31.01 | 2020-2021 | |
| Pfizer INC. | $30.08 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $20.73 | 2021 | |
| Azurity Pharmaceuticals, INC. | $17.73 | 2023 | Horizant |
| Novartis Pharmaceuticals Corporation | $16.72 | 2019 | |
| Dexcom, INC. | $16.15 | 2023 | Dexcom G6 Transmitter |
| Abbott Laboratories | $12.97 | 2021 | |
| Melinta Therapeutics, LLC | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olufonso Ojo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.